Do analysts recommend APRE or PYRGF?

Aprea Therapeutics presently has a consensus price target of $4.07, indicating a potential upside of 543.46%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aprea Therapeutics is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend BCTX or APRE?

Aprea Therapeutics has a consensus target price of $4.07, suggesting a potential upside of 543.46%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has better earnings and valuation, BCTX or APRE?

Briacell Therap is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A Aprea Therapeutics N/A N/A -$12.60M -$1.54 N/A

Aprea Therapeutics (APRE) Competitors

$0.63 +0.00 (+0.16%)

Closing price 07/24/2026 03:47 PM Eastern

Extended Trading

$0.64 +0.00 (+0.63%)

As of 07/24/2026 05:32 PM Eastern

Compare

APRE vs. GOSS, ALGS, PYRGF, LSTA, and BCTX

Should you buy Aprea Therapeutics stock or one of its competitors? MarketBeat compares Aprea Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aprea Therapeutics include Gossamer Bio (GOSS), Aligos Therapeutics (ALGS), PyroGenesis Canada (PYRGF), Lisata Therapeutics (LSTA), and Briacell Therap (BCTX). These companies are all part of the "pharmaceutical products" industry.

How does Aprea Therapeutics compare to Gossamer Bio?

Aprea Therapeutics (NASDAQ:APRE) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Aprea Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

Aprea Therapeutics currently has a consensus target price of $4.07, suggesting a potential upside of 543.46%. Gossamer Bio has a consensus target price of $3.20, suggesting a potential upside of 2,252.94%. Given Gossamer Bio's higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by insiders. Comparatively, 3.7% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Aprea Therapeutics and Aprea Therapeutics both had 1 articles in the media. Aprea Therapeutics' average media sentiment score of 1.87 equaled Gossamer Bio'saverage media sentiment score.

Company	Overall Sentiment
Aprea Therapeutics	Very Positive
Gossamer Bio	Very Positive

Aprea Therapeutics has higher earnings, but lower revenue than Gossamer Bio. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	N/A	N/A	-$12.60M	-$1.54	N/A
Gossamer Bio	$55.54M	0.57	-$170.37M	-$0.79	N/A

Gossamer Bio has a net margin of -324.82% compared to Aprea Therapeutics' net margin of -4,405.59%. Gossamer Bio's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%
Gossamer Bio	-324.82%	N/A	-96.10%

Summary

Gossamer Bio beats Aprea Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Aprea Therapeutics compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Aligos Therapeutics has a net margin of -1,919.68% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -61.03% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Aprea Therapeutics has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$4.71M	5.37	-$24.19M	-$8.69	N/A
Aprea Therapeutics	N/A	N/A	-$12.60M	-$1.54	N/A

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aligos Therapeutics has a beta of 2.26, meaning that its stock price is 126% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Aligos Therapeutics currently has a consensus price target of $38.50, indicating a potential upside of 843.63%. Aprea Therapeutics has a consensus price target of $4.07, indicating a potential upside of 543.46%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Aligos Therapeutics and Aligos Therapeutics both had 1 articles in the media. Aligos Therapeutics' average media sentiment score of 1.87 equaled Aprea Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aligos Therapeutics	Very Positive
Aprea Therapeutics	Very Positive

Summary

Aligos Therapeutics beats Aprea Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Aprea Therapeutics compare to PyroGenesis Canada?

Aprea Therapeutics (NASDAQ:APRE) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 10.5% of Aprea Therapeutics shares are owned by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aprea Therapeutics has higher earnings, but lower revenue than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	N/A	N/A	-$12.60M	-$1.54	N/A
PyroGenesis Canada	$9.14M	3.56	-$21.12M	-$0.04	N/A

In the previous week, Aprea Therapeutics had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 1 mentions for Aprea Therapeutics and 0 mentions for PyroGenesis Canada. Aprea Therapeutics' average media sentiment score of 1.87 beat PyroGenesis Canada's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aprea Therapeutics	Very Positive
PyroGenesis Canada	Neutral

Aprea Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Aprea Therapeutics presently has a consensus price target of $4.07, indicating a potential upside of 543.46%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aprea Therapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PyroGenesis Canada has a net margin of -115.14% compared to Aprea Therapeutics' net margin of -4,405.59%. PyroGenesis Canada's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%
PyroGenesis Canada	-115.14%	N/A	-60.81%

Summary

Aprea Therapeutics beats PyroGenesis Canada on 10 of the 15 factors compared between the two stocks.

How does Aprea Therapeutics compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 9.6% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 798.20%. Aprea Therapeutics has a consensus target price of $4.07, indicating a potential upside of 543.46%. Given Lisata Therapeutics' higher probable upside, analysts plainly believe Lisata Therapeutics is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Lisata Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

In the previous week, Lisata Therapeutics had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 3 mentions for Lisata Therapeutics and 1 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.87 beat Lisata Therapeutics' score of 0.56 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lisata Therapeutics	Positive
Aprea Therapeutics	Very Positive

Aprea Therapeutics has lower revenue, but higher earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	89.45	-$16.59M	-$1.86	N/A
Aprea Therapeutics	N/A	N/A	-$12.60M	-$1.54	N/A

Lisata Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -61.03% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Summary

Aprea Therapeutics beats Lisata Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Aprea Therapeutics compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Briacell Therap has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -61.03% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Briacell Therap is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Aprea Therapeutics	N/A	N/A	-$12.60M	-$1.54	N/A

Briacell Therap has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Aprea Therapeutics has a consensus target price of $4.07, suggesting a potential upside of 543.46%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Briacell Therap and Briacell Therap both had 1 articles in the media. Briacell Therap's average media sentiment score of 1.89 beat Aprea Therapeutics' score of 1.87 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Overall Sentiment
Briacell Therap	Very Positive
Aprea Therapeutics	Very Positive

Summary

Aprea Therapeutics beats Briacell Therap on 11 of the 13 factors compared between the two stocks.

Get Aprea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APRE vs. The Competition

Export

Metric	Aprea Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.81M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.41	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.06	88.99
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.42	7.88	10.28	6.07
Net Income	-$12.60M	$23.86M	$3.60B	$331.99M
7 Day Performance	-7.06%	-3.82%	-1.27%	-0.63%
1 Month Performance	-19.99%	-2.61%	-0.37%	-2.00%
1 Year Performance	-66.56%	32.79%	18.30%	13.62%

Aprea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APRE Aprea Therapeutics	4.1421 of 5 stars	$0.63 +0.2%	$4.07 +543.5%	-67.3%	$7.81M	N/A	N/A	7	Gap Up
GOSS Gossamer Bio	2.5773 of 5 stars	$0.15 +9.8%	$3.20 +1,967.2%	-92.4%	$33.09M	$55.54M	N/A	180	Positive News
ALGS Aligos Therapeutics	3.7084 of 5 stars	$5.44 +3.0%	$38.50 +607.7%	-54.2%	$32.67M	$4.71M	N/A	90	Positive News Gap Up
PYRGF PyroGenesis Canada	N/A	$0.13 -2.4%	N/A	-55.6%	$32.25M	$9.14M	N/A	90	Gap Up
LSTA Lisata Therapeutics	1.9684 of 5 stars	$2.24 -36.5%	$15.00 +569.6%	-37.2%	$32.10M	$170K	N/A	30	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APRE) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aprea Therapeutics (APRE) Competitors

APRE vs. GOSS, ALGS, PYRGF, LSTA, and BCTX

How does Aprea Therapeutics compare to Gossamer Bio?

Summary

How does Aprea Therapeutics compare to Aligos Therapeutics?

Summary

How does Aprea Therapeutics compare to PyroGenesis Canada?

Summary

How does Aprea Therapeutics compare to Lisata Therapeutics?

Summary

How does Aprea Therapeutics compare to Briacell Therap?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aprea Therapeutics (APRE) Competitors

APRE vs. GOSS, ALGS, PYRGF, LSTA, and BCTX

How does Aprea Therapeutics compare to Gossamer Bio?

Which has more volatility & risk, APRE or GOSS?

Do analysts rate APRE or GOSS?

Do insiders & institutionals have more ownership in APRE or GOSS?

Does the media refer more to APRE or GOSS?

Which has preferable valuation and earnings, APRE or GOSS?

Is APRE or GOSS more profitable?

Summary

How does Aprea Therapeutics compare to Aligos Therapeutics?

Is ALGS or APRE more profitable?

Which has higher earnings and valuation, ALGS or APRE?

Do insiders & institutionals believe in ALGS or APRE?

Which has more volatility and risk, ALGS or APRE?

Do analysts prefer ALGS or APRE?

Does the media prefer ALGS or APRE?

Summary

How does Aprea Therapeutics compare to PyroGenesis Canada?

Do institutionals & insiders believe in APRE or PYRGF?

Which has better valuation and earnings, APRE or PYRGF?

Does the media favor APRE or PYRGF?

Which has more volatility and risk, APRE or PYRGF?

Do analysts recommend APRE or PYRGF?

Is APRE or PYRGF more profitable?

Summary

How does Aprea Therapeutics compare to Lisata Therapeutics?

Do institutionals and insiders believe in LSTA or APRE?

Do analysts recommend LSTA or APRE?

Which has more volatility & risk, LSTA or APRE?

Does the media prefer LSTA or APRE?

Which has better valuation and earnings, LSTA or APRE?

Is LSTA or APRE more profitable?

Summary

How does Aprea Therapeutics compare to Briacell Therap?

Do insiders & institutionals have more ownership in BCTX or APRE?

Is BCTX or APRE more profitable?

Which has better earnings and valuation, BCTX or APRE?

Which has more volatility and risk, BCTX or APRE?

Do analysts recommend BCTX or APRE?

Does the media refer more to BCTX or APRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools